Format

Send to

Choose Destination
See comment in PubMed Commons below
Hematol Oncol Clin North Am. 2012 Jun;26(3):589-605, viii. doi: 10.1016/j.hoc.2012.02.001. Epub 2012 Mar 2.

Tyrosine kinase inhibitors in lung cancer.

Author information

1
Medical Oncology Branch, National Cancer Institution, Room 12N226, 10 Center Drive, Bethesda, MD 20892, USA.

Abstract

Identification of driver mutations in growth related protein kinases, especially tyrosine kinases, has led to clinical development of an array of tyrosine kinase inhibitors in various malignancies, including lung cancer. Improved understanding of tyrosine kinase biology has led to faster drug development, identification of resistance mechanisms, and ways to overcome resistance. This review discusses the clinical data supporting the use and practical aspects of management of patients on epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors.

PMID:
22520981
PMCID:
PMC3334853
DOI:
10.1016/j.hoc.2012.02.001
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center